Call the HEPLISAV-B Pregnancy Registry toll-free number 1-844-443-7734
OR email: heplisavbpregnancyregistry@ppdi.com
INDICATION AND IMPORTANT SAFETY INFORMATION

Why enroll in the HEPLISAV-B Pregnancy Registry?

We encourage you to voluntarily enroll in the HEPLISAV-B Pregnancy Registry and help us learn more about the health of infants born to mothers who were vaccinated with HEPLISAV-B within 28 days prior to conception or during pregnancy. Your participation may help other women and their babies in the future.

What is required of me to participate?

  • You must be at least 18 years of age.
  • You must currently be pregnant, or have already delivered and your infant has been diagnosed with a birth defect.
  • You must have received a dose of the hepatitis B vaccine HEPLISAV-B within 28 days prior to conception or during your pregnancy. You will not be vaccinated as part of the study.
  • You must agree to provide Personal and Healthcare Provider contact information and consent for release of medical information for yourself and your infant. Once enrolled we will collect all necessary information from you and your infant’s respective healthcare providers.

Is it easy to enroll in the Registry?

Yes, there are three simple ways to contact the Registry staff.

Ways to enroll in the HEPLISAV-B® Pregnancy Registry

Call Heplisav-B Pregnancy Registry
Call our toll-free number
Download Participant Consent form
Download
(Fill it out and send it to us via email or fax (1-877-202-3940))

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

References: 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020.2. Dynavax’s HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults [news release]. Emeryville, CA: Dynavax Technologies Corporation. http://investors.dynavax.com/news-releases/newsrelease-details/dynavaxs-heplisav-btm-hepatitis-b-vaccine-recombinant-adjuvanted. Accessed March 15, 2018.

CLICK HERE FOR FULL PRESCRIBING INFORMATION
Heplisav-B